Serum and urine adropin levels following urinary microalbuminuria in patients with type 2 diabetes

Year 2024, Volume: 3 Issue: 7, 96 - 104, 31.12.2024

Burak Öz , Ahmet Karatas , Kader Uğur , Süleyman Aydın , Nevzat Gözel

https://doi.org/10.56150/tjhsl.1575803

Abstract

ABSTRACT
Objective:
Diabetes mellitus disrupts energy balance due to insulin deficiency or resistance, presenting a significant public health challenge. A major complication is end-stage renal disease (ESRD), primarily resulting from diabetic nephropathy. Peptide hormones significantly contribute to the pathogenesis of diabetes. Adropin, a peptide hormone associated with energy regulation, has an unclear relationship with diabetes and nephropathy. This study aims to evaluate serum and urinary adropin levels in diabetic patients and explore the correlation between these levels and diabetic nephropathy occurrence.
Materials and Methods
In this cross-sectional study, serum and urine adropin levels were measured via enzyme-linked immunosorbent assay (ELISA) in 60 diabetic patients categorized by normoalbuminuria, microalbuminuria, and overt albuminuria, alongside 20 healthy controls.
Results:
Serum adropin levels were significantly lower in healthy controls, normoalbuminuric, and microalbuminuric groups compared to the overt albuminuric group (p=0.007, p<0.001, p=0.008). Adropin positively correlated with serum creatinine and microalbuminuria levels (p=0.031, r=0.242; p=0.001, r=0.379). Urinary adropin levels were significantly higher in diabetic patients than in controls (p=0.001) and lower in the microalbuminuric group compared to both normoalbuminuric and overt albuminuric groups (p=0.026 for both).
Conclusion:
Adropin levels are significantly altered in diabetic nephropathy, highlighting its potential as both a biomarker and a therapeutic target due to its involvement in insulin sensitivity, inflammation, and metabolic pathways. Future research should investigate the mechanisms through which adropin influences renal function and its therapeutic potential in metabolic disorders, especially in diabetic kidney disease, while also addressing the implications of adropin resistance.

Keywords

Adropin, Diabetes mellitus, Diabetic Nephropathy

Ethical Statement

This study was approved by the Fırat University Faculty of Medicine Clinical Studies Ethics Committee (97521439-110/13-02-03).

Supporting Institution

This research received no grant from any funding agency/sector.

Thanks

I would like to express my gratitude to all my professors who provided invaluable assistance in the preparation of my thesis, as well as to the Fırat University Endocrinology Clinic.

References

• Ceriello A., Prattichizzo F., Variability of risk factors and diabetes complications, Cardiovascular diabetology 20(1), (2021), 101.
• Abdul Basith Khan M., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J., Epidemiology of type 2 diabetes—global burden of disease and forecasted trends, Journal of epidemiology and global health 10(1), (2020), 107-111.
• Samsu N., Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment, BioMed research international 2021(1), (2021), 1497449.
• Qi C., Mao X., Zhang Z., Wu H., Classification and differential diagnosis of diabetic nephropathy, Journal of diabetes research 2017(1), (2017), 8637138.
• Thipsawat S., Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature, Diabetes and Vascular Disease Research 18(6), (2021), 14791641211058856.
• Elendu C., Okah M.J., Fiemotongha K.D., Adeyemo B.I., Bassey B.N., Omeludike E.K., Obidigbo B., Comprehensive advancements in the prevention and treatment of diabetic nephropathy: A narrative review, Medicine 102(40), (2023), e35397.
• Ali I.I., D’Souza C., Singh J., Adeghate E., Adropin’s role in energy homeostasis and metabolic disorders, International journal of molecular sciences 23(15), (2022), 8318.
• Jasaszwili M., Billert M., Strowski M.Z., Nowak K.W., Skrzypski M., Adropin as a fat-burning hormone with multiple functions—Review of a decade of research, Molecules 25(3), (2020), 549.
• Gunraj R.E., Yang C., Liu L., Larochelle J., Candelario-Jalil E., Protective roles of adropin in neurological disease, American Journal of Physiology-Cell Physiology 324(3), (2023), C674-C678.
• Es-Haghi A., Al-Abyadh T., Mehrad-Majd H., The clinical value of serum adropin level in early detection of diabetic nephropathy, Kidney and Blood Pressure Research 46(6), (2021), 734-740.
• Hu W., Chen L., Association of serum adropin concentrations with diabetic nephropathy, Mediators of inflammation 2016(1), (2016), 6038261.
• Soltani S., Beigrezaei S., Malekahmadi M., Clark C.C., Abdollahi S., Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies, BMC Endocrine Disorders 23(1), (2023), 73.
• Yu M., Wang D., Zhong D., Xie W., Luo J., Adropin carried by reactive oxygen species-responsive nanocapsules ameliorates renal lipid toxicity in diabetic mice, ACS Applied Materials & Interfaces 14(33), (2022), 37330-37344.
• Li B., Tian X., Guo S., Zhang M., Li J., Zhai N., Wang H., Zhang Y., Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients, International urology and nephrology 52(11), (2020), 2145-2152.
• Berezina T.A., Obradovic Z., Boxhammer E., Berezin A.A., Lichtenauer M., Berezin A.E., Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure, Journal of Clinical Medicine 12(6), (2023), 2231.
• Prystupa A., Kiciński P., Luchowska-Kocot D., Sak J., Prystupa T., Chen K.-H., Chen Y.-H., Panasiuk L., Załuska W., Afamin and adropin in patients with alcohol-induced liver cirrhosis, Annals of Agricultural and Environmental Medicine 25(3), (2018), 527-531.
• Taha M.M., Muhsen S.N., Evaluation of Adropin Levels in Cardiovascular Disease, Journal of Prevention, Diagnosis and Management of Human Diseases 4(01), (2024), 22-30. https://doi.org/10.55529/jpdmhd.41.22.30
• Li N., Xie G., Zhou B., Qu A., Meng H., Liu J., Wang G., Serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease, Frontiers in physiology 12 (2021), 696163.
• Ashour W.M., Abdel-Aleem D., Khalil S.S., Elkazzaz O.M., Serum adropin and vaspin levels in obese rats with polycystic ovary syndrome and after metformin treatment, Zagazig University Medical Journal 27(2), (2021), 193-202.
• Rayego-Mateos S., Rodrigues-Diez R.R., Fernandez-Fernandez B., Mora-Fernández C., Marchant V., Donate-Correa J., Navarro-González J.F., Ortiz A., Ruiz-Ortega M., Targeting inflammation to treat diabetic kidney disease: the road to 2030, Kidney international 103(2), (2023), 282-296.
• Kaur R., Krishan P., Kumari P., Singh T., Singh V., Singh R., Ahmad S.F., Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease, Diagnostics 13(19), (2023), 3158.
• Azab M.M.A., Mady N.M., El Bendary E.M., El Sawy S.A., A Cross Talk Between Adropin and Possible Metabolic Syndrome Disorders in Experimental Male Albino Rats, International journal of health sciences 6(S4), 9815-9834.
• Guo L., Jiang B., Li D., Xiao X., Nephroprotective effect of adropinin against streptozotocin-induced diabetic nephropathy in rats: inflammatory mechanism and YAP/TAZ factor, Drug Design, Development and Therapy (2021), 589-600.
• Rizk F.H., El‐Saka M.H., Ibrahim R.R., El‐Deeb O.S., Ibrahim H.A., El Saadany A.A., Mashal S.S., Ammar L., Abdelsattar A.M., Barhoma R.A., Possible mitigating effect of adropin on lung injury in diabetic rats: Targeting the role of Rho A/Rho‐associated kinase pathway, BioFactors 49(4), (2023), 928-939.
• Thapa D., Stoner M.W., Zhang M., Xie B., Manning J.R., Guimaraes D., Shiva S., Jurczak M.J., Scott I., Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway, Redox biology 18 (2018), 25-32.
• Stevens J.R., Kearney M.L., St‐Onge M.P., Stanhope K.L., Havel P.J., Kanaley J.A., Thyfault J.P., Weiss E.P., Butler A.A., Inverse association between carbohydrate consumption and plasma adropin concentrations in humans, Obesity 24(8), (2016), 1731-1740.
• Butler A.A., St-Onge M.-P., Siebert E.A., Medici V., Stanhope K.L., Havel P.J., Differential responses of plasma adropin concentrations to dietary glucose or fructose consumption in humans, Scientific reports 5(1), (2015), 14691.
• Stelcer E., Milecka P., Komarowska H., Jopek K., Tyczewska M., Szyszka M., Lesniczak M., Suchorska W., Bekova K., Szczepaniak B., Adropin stimulates proliferation and inhibits adrenocortical steroidogenesis in the human adrenal carcinoma (HAC15) cell line, Frontiers in endocrinology 11 (2020), 561370.
• Ganesh‐Kumar K., Zhang J., Gao S., Rossi J., McGuinness O.P., Halem H.H., Culler M.D., Mynatt R.L., Butler A.A., Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance, Obesity 20(7), (2012), 1394-1402. https://doi.org/10.1038/oby.2012.31
• Gao S., McMillan R.P., Zhu Q., Lopaschuk G.D., Hulver M.W., Butler A.A., Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance, Molecular metabolism 4(4), (2015), 310-324.
• Zhang S., Chen Q., Lin X., Chen M., Liu Q., A review of adropin as the medium of dialogue between energy regulation and immune regulation, Oxidative medicine and cellular longevity 2020(1), (2020), 3947806.
• Yazgan B., Avcı F., Memi G., Tastekin E., Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin, Experimental Biology and Medicine 246(17), (2021), 1917-1927.
• Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta M., Al-Omran M., Teoh H., Verma S., Adropin is a novel regulator of endothelial function, Circulation 122(11_suppl_1), (2010), S185-S192.
• Ibrahim M.E., El-Din D.N., Alkot A.M., Mansour A.E., Amer H.G., Assessment of serum adropin level in type 2 diabetic patients with or without nephropathy, Journal of The Arab Society for Medical Research 16(1), (2021), 17-23.
• Gu X., Li H., Zhu X., Gu H., Chen J., Wang L., Harding P., Xu W., Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: A cross-sectional study, Medicine 94(40), (2015), e1712.
• Chachan T.A.K.A., Farhna H., Hamed S., Jawad A.A., Determination of adropin, body mass index and other biochemical parameters in Iraqi type II diabetic patients, International Journal of Health Sciences (V), (2022), 431322.
• Alzoughool F., Al Hourani H., Atoum M., Bateineh S., Abu shaikh H., Al-Zghool H., Al-Shudifat A.-e., Evaluation of serum adropin and irisin levels and its association with anthropometric obesity indices and biochemical parameters in Type 2 diabetic patients, Nutrition and Healthy Aging 6(3), (2021), 191-198.
• Memi G., Yazgan B., Adropin and spexin hormones regulate the systemic inflammation in adenine-induced chronic kidney failure in rat, Journal of Physiology Investigation 64(4), (2021), 194-201.